Gloucester Pharmaceuticals, Inc.
One Broadway, Suite 600
Cambridge
Massachusetts
02142
United States
Tel: 617-621-1561
Fax: 617-577-1209
Website: http://www.gloucester-pharma.com/
Email: contact@gloucesterpharma.com
43 articles about Gloucester Pharmaceuticals, Inc.
-
VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.
-
Celgene Completes Acquisition of Gloucester Pharmaceuticals, Inc.
1/15/2010
-
Celgene (JOBS) to Buy Gloucester Pharmaceuticals, Inc. in Cancer Drug Deal; Celgene to Pay $340 Million in Cash, $300 Million in Milestones
12/8/2009
-
Gloucester Pharmaceuticals, Inc. Presents ISTODAX(R) Data Demonstrating Clinical Benefit in Patients with CTCL Including Blood Involvement at American Society of Hematology Annual Meeting
12/7/2009
-
Gloucester Pharmaceuticals, Inc. Release: ISTODAX(R) Incorporated Into National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology(TM) for the Treatment of Cutaneous T-cell Lymphoma (CTCL)
12/3/2009
-
Gloucester Pharmaceuticals, Inc. to Present Positive Results from Multiple Studies of ISTODAX(R) at the American Society of Hematology Annual Meeting
11/25/2009
-
FDA Approves Gloucester Pharmaceuticals, Inc.'s ISTODAX(R) for Patients with Cutaneous T-cell Lymphoma
11/6/2009
-
FDA Advisory Committee Recommends Gloucester Pharmaceuticals, Inc.'s Romidepsin for Approval for Cutaneous T-cell Lymphoma
9/3/2009
-
Gloucester Pharmaceuticals, Inc. Gears Up for FDA Panel Vote on Lymphoma Drug
9/2/2009
-
Gloucester Pharmaceuticals, Inc. Completes $29 Million Financing
8/25/2009
-
Gloucester Pharmaceuticals, Inc. Announces FDA Advisory Committee Meeting to Discuss Romidepsin New Drug Application
8/17/2009
-
Gloucester Pharmaceuticals, Inc. to Present New Data from Two Studies on Romidepsin at American Society of Clinical Oncology
5/29/2009
-
Gloucester Pharmaceuticals, Inc. Announces Positive Results from Phase 1/2 Multiple Myeloma Clinical Trial at American Society of Hematology
12/9/2008
-
Gloucester Pharmaceuticals, Inc. Announces Positive Results from Romidepsin T-cell Lymphoma Clinical Trials at American Society of Hematology
12/8/2008
-
Gloucester Pharmaceuticals, Inc. to Present Positive Results From Multiple Romidepsin Clinical Trials at the American Society of Hematology Annual Meeting
11/20/2008
-
Gloucester Pharmaceuticals, Inc. Announces Phase 2 Data for Romidepsin Showing Durable Response in Refractory CTCL
6/17/2008
-
Gloucester Pharmaceuticals, Inc. Announces Podium Presentation of Positive Results from Phase 2b Registration Trial of Romidepsin in Refractory CTCL
6/5/2008
-
Gloucester Pharmaceuticals, Inc. Announces Presentation of Romidepsin Phase 1 Data in Multiple Solid Tumors at American Society of Clinical Oncology
6/2/2008
-
Gloucester Pharmaceuticals, Inc. Announces Positive Results from Phase 2b Registration Trial of Romidepsin in Refractory CTCL
5/19/2008
-
Gloucester Pharmaceuticals, Inc. Announces New Senior Management Team, New CEO and COO
1/28/2008